CUPERTINO, Ca., Nov. 7 /PRNewswire/ — In conjunction with DURECT
Corporation’s (Nasdaq: DRRX) third quarter financial results press release,
you are invited to listen to its conference call that will be broadcast live
over the Internet on Monday, November 13, 2000 at 4:30 p.m. EST with Jim
Brown, President and Chief Executive Officer, Tom Schreck, Chief Financial
Officer, and Schond Greenway, Director, Investor Relations.
|What:||DURECT Corporation third quarter earnings conference call|
|When:||Monday, November 13, 2000, 4:30 p.m. EST|
|How:||Live over the Internet — Simply log on to the Web at the|
|address listed above or access through DURECT’s Website|
|Contact:||Andi Wakayama, Noonan/Russo Communications,|
|415-677-4455, ext. 252|
DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems that will deliver the right drug to the right site in
the right amount at the right time. DURECT’s pharmaceutical systems combine
technology innovations from the medical device and drug delivery industries
with proprietary pharmaceutical and biotechnology drug formulations. These
capabilities can enable new drug therapies or optimize existing therapies
based on a broad range of compounds, including small molecule pharmaceuticals
as well as biotechnology molecules such as proteins, peptides and genes.
DURECT’s initial portfolio of products combine the DUROS technology, a proven
and patented drug delivery platform licensed for specified fields of use from
ALZA Corporation, with drugs for which medical data on efficacy and safety are
available. Founded in 1998, the Company is headquartered in Cupertino, CA.
The Company’s World Wide Web site can be accessed at http://www.www.durect.com.
To join DURECT’s email alert service, please register by selecting “Email
Alerts” on the main Investor Relations web page at http://www.www.durect.com.
DUROS is a registered trademark of ALZA Corporation.
If you are unable to participate during the live webcast, the call will be
archived at: http://www.www.durect.com/wt/frame.php?page_name=investor
Minimum Requirements to listen to broadcast: The RealPlayer software,
downloadable free from http://www.real.com/products/player/index.html, and at
least a 14.4Kbps connection to the Internet. If you experience problems
listening to the broadcast, send an email to email@example.com.)
The statements in this press release regarding DURECT’s products in
development, product development plans, clinical trials, and expected product
benefits are forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties include, but
are not limited to, DURECT’s ability to develop, manufacturer and
commercialize its products, complete successful clinical trials, obtain
product approvals from regulatory agencies, build a manufacturing facility and
marketplace acceptance of DURECT’s products. Further information regarding
these and other risks is included in the company’s S-1 registration statement,
filed with the SEC on September 22, 2000 and its 424(b) prospectus filed with
the SEC on September 28, 2000.
SOURCE DURECT Corporation
CONTACT: Andi Wakayama, 415-677-4455, ext. 252 for DURECT Corporation